Jump to content
African American Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Search the Community

Showing results for tags 'wellness fitness', ' healthcare', ' rootsanalysis', ' informationservices', ' marketresearch', ' research', ' medicaldevices', ' pharma' or ' pharmaceutical'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • African Americans Condition
    • General chat for African Americans
    • Opinions and News about the Discriminations and Maltreatments of the African Americans
    • Martin Luther King life
    • Malcolm X life
    • Barack Obama life
    • Michael Jeffrey Jordan life
    • Michael Jackson life
    • African American Celebrities
    • Is Racism Coming Back?
    • History of African Americans
    • Marriage and De facto Couples Interracial
    • Is the African American Community impoverishing?
    • Is the Government's Penal Policy Racist?
    • African American Dating
  • Opinions of the African Americans
    • Health Care and African Americans
    • Politics and African Americans
    • Religion and African Americans
    • Instruction and African Americans
    • Career and African Americans
    • Art and Artists for African Americans
    • Music for African Americans
    • Cinema for African Americans
    • Sports and African Americans
    • Television and African Americans
    • Books and African Americans
    • Cooking and African Americans
    • Games for African Americans
  • Presidency of Barack Obama's Brief history of Barack Obama's presidency

Blogs

  • Life of Martin Luther King Jr.
  • stefan will
  • Kevin Doe
  • Steffan Joe
  • Damon Salvatore
  • Michael Doe
  • Mason Joe
  • medical research
  • RootsAnalysis Diary

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


About Me

  1. Report Keywords - Cloud-based Solutions, Cloud, Drug Discovery, RootsAnalysis, Report, Biotech The growing complexities surrounding modern therapy development initiatives have caused biopharmaceutical companies to adopt available cloud-based solutions, to not only expedite associated timelines, but also cuts down overall cost Roots Analysis has announced the addition of “Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market by Type of Cloud (Private, Public and Hybrid), Type of Service (Infrastructure as a Service (IaaS), Platform as a Service (PaaS) and Software as a Service (SaaS)), End-User (Biotech Vendors, Contract Research Organizations, Pharmaceutical Companies and Others), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings. Modern cloud-based solutions offer decentralized / real world data management, and collaborative operating solutions to users, enabling the simplification and delegation of various aspects of data mining, analysis and healthcare decision-making. The implementation of relevant cloud-based solutions is deemed to possess the potential to save over 50% of the total cost and time invested in a drug development program. To order this 225+ page report, which features 110+ figures and 130+ tables, please visit https://www.rootsanalysis.com/reports/cloud-based-solutions-in-healthcare-market.html Key Market Insights More than 60 cloud-based service providers are presently offering cloud-based solutions to pharma / biotech companies Majority of these are large firms (500+ employees, 44%), followed by small (1-50 employees, 32%), and mid-sized (51-500 employees, 24%) business entities. Over 50 service providers claim to offer cloud-based solutions for drug development About 50% players are providing cloud services for more than one area of application (drug discovery, drug development, or drug manufacturing) to pharma / biotech companies. Nearly 30 service providers claim to offer private cloud-based solutions to ensure data security Interestingly, about 25% players are offering all three types of cloud-based solutions (private, public and hybrid) to developer companies. Prominent examples of companies offering hybrid cloud include (in alphabetical order with no selection criteria) Informatica, Nutanix, QMENTA, Rescale, SureClinical, Tata Consultancy Services and YASH Technologies. Partnership activity in this field has grown at a CAGR of ~75%, between 2015 and 2020 Around 70% of the reported deals were established after 2018, with the maximum activity being reported in 2020. Majority of the instances captured in the report are research agreements (32%) and platform development / improvement agreements (26%). Adoption of cloud-based solutions has demonstrated the ability to enable up to 50% cost savings Based on inputs from both secondary and primary sources, the report features an informed and insightful analysis, estimating cost saving potential of cloud-based solutions. In fact, the adoption of such technologies has the potential to save more than USD 30 billion in drug discovery, USD 13 billion in drug development and USD 6.6 million in drug manufacturing related costs, by 2030. North America, Europe and Asia are anticipated to capture over 85% of the market share by 2030 Owing to increased adoption rates, the market in Asia is anticipated to grow at a relatively faster pace at a CAGR of 16%. In 2030, cloud-based solutions for drug development are likely to capture the largest market share (45%) in terms of revenues generated from use of such services, followed by those intended for drug discovery (35%) and drug development (20%) operations. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/cloud-based-solutions-in-healthcare-market/request-sample.html Key Questions Answered § Who are the leading players offering cloud-based solutions for drug discovery, development and manufacturing? § What kind of cloud services are commonly offered by companies in this domain? § What kind of partnership models are commonly adopted by stakeholders in this industry? § What is the likely cost saving potential associated with the use of cloud-based solutions in drug discovery, development and manufacturing processes? § How is the current and future opportunity likely to be distributed across key market segments? § What kind of performance enhancements are possible by integrating artificial intelligence, deep learning, machine learning and quantum computing, with existing cloud-based solutions? § What is the impact of the COVID-19 pandemic within this market? The USD 20 billion (by 2030) financial opportunity within the cloud-based solutions for drug discovery, drug development and drug manufacturing market has been analyzed across the following segments: § Type of Cloud Private Public Hybrid § Type of Cloud Service IaaS PaaS SaaS § Area of Application Drug Discovery Drug Development Drug Manufacturing § End-User Biotech Vendor Contract Research Organizations Pharmaceutical Companies Others § Key Geographical Regions North America Europe Asia-Pacific Middle East and North Africa Latin America Rest of the World The research includes brief profiles of key players engaged in offering cloud-based solutions for drug discovery, development and manufacturing; other popular industry players featured in the report include: § Accenture § Alibaba Cloud § Amazon Web Services § ChemAxon § CloudSigma § Google § IBM § Nimbix § OpenEye Scientific § Oracle § Skyland Analytics § Veeva Systems § XtalPi § YPrime You may also be interested in the following titles: 1. Digital Solutions for Biomarkers Market, 2021-2030 2. AI-based Drug Discovery Market: Focus on Deep Learning and Machine Learning, 2020-2030 3. In Silico / Computer-Aided Drug Discovery Services Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis
  2. Report Keywords - Antibody Contract, Contract, Manufacturing Market, RootsAnalysis, Report With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings. Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. Key Market Insights Over 100 CMOs presently claim to offer manufacturing services for antibodies The antibody contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial). More than 90% service providers are focused on the production of monoclonal antibodies However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments. For more Insightful Information - https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html Europe has emerged as a key manufacturing hub for antibody-based products More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan. More than 90 partnership agreements have been inked between 2013 and 2019 Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%). Multiple expansion initiatives were undertaken by CMOs between 2017 and 2019 More than 50% of such initiatives were reported to be focused on the expansion of manufacturing facilities, followed by building new facilities (38%). It is worth noting that close to 50% of the total number of expansion initiatives were undertaken in Europe, of which, 25% were in the UK. Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025 Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand. Across the three major global regions, North America represent over half of the overall global manufacturing demand for antibodies. North America and Europe are anticipated to capture over 70% of the market share by 2030 However, the market in the Asia is anticipated to grow at a relatively faster rate. Further, presently, more than 90% of the antibodies are being developed using mammalian expression systems, and this trend is unlikely to change significantly in short to mid-term. To request a sample copy of Report - https://www.rootsanalysis.com/reports/antibody-cmo-market/request-sample.html Key Questions Answered § Who are the leading CMOs engaged in the production of antibody-based therapeutics? § What kind of partnership models are commonly adopted by stakeholders in this industry? § What is the annual clinical and commercial demand for antibody-based products? § What is the current installed capacity for manufacturing of antibodies? § What are the various expansion initiatives undertaken by antibody CMOs? § How is the current and future market opportunity likely to be distributed across key market segments? The USD 17 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments: § Type of Antibodies § Monoclonal Antibodies § Bispecific Antibodies § ADCs § Others § Company Size § Small § Mid-sized § Large / Very Large § Scale of Operation § Preclinical / Clinical § Commercial § Type of expression system used § Mammalian § Microbial § Key geographical regions § North America § Europe § Asia and RoW The report features inputs from eminent industry stakeholders, according to whom antibody therapeutics developers are increasingly outsourcing their manufacturing operations owing to complex nature of the overall process, as well as the high investments associated with setting-up in-house expertise. The report includes detailed transcripts of discussions held with the following experts: § Dietmar Katinger (Chief Executive Officer, Polymun Scientific) § David C Cunningham (Director, Corporate Development, Goodwin Biotechnology) § Claire Otjes (Marketing Manager, Batavia Biosciences) The research covers profiles of key players that offer manufacturing services for antibodies, featuring a company overview, information on their respective service portfolios, manufacturing facilities and capabilities, and an informed future outlook. § AGC Biologics § Aldevron § AMRI § Boehringer Ingelheim BioXcellence § Emergent BioSolutions § Eurofins CDMO § FUJIFILM Diosynth Biotechnologies § KBI Biopharma § Lonza § Nitto Avecia Pharma Services § Novasep § Pierre Fabre § Samsung BioLogics § Synthon § Thermo Fisher Scientific You may also be interested in the following titles: 1. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 2. Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030 3. Antibody Drug Conjugates Market (5th Edition), 2019-2030 4. Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis
  3. Over the years, outsourcing has become a popular trend with the medical device industry, allowing innovators to leverage the technical and regulatory expertise of contract service providers in order to expedite time to market Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CROs for Regulatory Affairs Management Market, 2019-2030.” The report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices. The study features an in-depth analysis, highlighting the capabilities of the various CROs engaged in this domain, across different regions of the globe. Amongst other elements, the report includes: § A detailed review of the current market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain. § A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies. § An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, Asia-Pacific and rest of the world. § Elaborate profiles of popular players that specialize in offering end-to-end regulatory services for medical devices across key geographies. § A benchmark analysis, highlighting the key focus areas of very small-sized, small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups. § An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner. § An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research. § A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers. § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) § Medical Device Class § Class I § Class II § Class III § Therapeutic Area § Cardiovascular Disorders § CNS Disorders § Metabolic Disorders § Oncological Disorders § Ophthalmological Disease § Orthopedic Disorders § Pain Disorders § Respiratory Disorders § Others § Type of Regulatory Affairs Service § Pharmacies GAP-Analysis § Pharmacies Legal Representation § Pharmacies Notified Body Selection § Product Labelling-related Services § Product Registration and Clinical Trial Applications § Regulatory Document Submissions § Regulatory Writing and Publishing § Risk Management-related Services § Technical Dossier Set-up § Vigilance & Medical Device Report § Key Geographical Regions § North America § Europe § Asia-Pacific and Rest of the World Key companies covered in the report § CTI Clinical Trial and Consulting Services § CROMSOURCE § ICON § Intertek § Medpace § MIC Medical § North American Science Associates (NAMSA) § Parexel § PharmaLex § Premier Research § Société Générale de Surveillance (SGS) § Underwriters Laboratory (UL) For more information please click on the following link https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html Other Recent Offerings 1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 2. Medical Device Labels Manufacturing Market, 2019-2030 3. Medical Device Contract Manufacturing Market, 2019-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  4. Report Keywords- Healthcare, Digital Marketing, Healthcare Digital Marketing, Pharma, Biotech Given the present scenario, many stakeholders are adopting such advanced marketing strategies to drive better consumer engagement through the use of immersive and interactive technologies Roots Analysis has announced the addition of “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” report to its list of offerings. Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes. These technologies have been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors. Given the increasing demand for immersive technologies in the healthcare and pharma marketing, several stakeholders are expected to forge alliances with AR / VR service providers in the foreseen future. Owing to the rising interest of big pharma players in this domain, we expect an escalated industry-wide adoption of such technologies. To order this 180+ page report, which features 45+ figures and 70+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/healthcare-digital-marketing/323.html Key Market Insights More than 125 companies claim to offer different AR / VR based digital marketing services to the healthcare and pharma industry. The majority of players engaged in providing AR / VR based digital marketing services to the healthcare and pharmaceutical industry are small-sized companies (63%), followed by mid-sized (32%) and large players (5%). In addition, majority (38%) of the players were established during the period 2011-2015. Several big pharma players have taken significant strides in in the field of AR / VR These instances are either by collaborating with digital marketing service providers or through development of in-house capabilities. Majority (18%) of the instances were recorded in the year 2018. More than 350 industry players have been identified as likely partners for AR / VR based digital marketing service providers The potential strategic partners have been identified by evaluating more than 4,500 industry sponsored clinical trials (including phase I / II, phase II and phase II / III trials), and have been analyzed based on our proprietary scoring criteria. Currently, a significant proportion (57%) of service revenues is generated from AR based digital marketing projects In 2020, VR based projects are anticipated to contribute to 42% of the overall market share. It is worth mentioning that, in the foreseen future, service revenues generated through MR based technologies are anticipated to grow at a CAGR of 5% till 2030. To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/323/request-sample.html Key Questions Answered § Who are the leading players offering AR / VR based digital marketing services? § Which immersive technology, AR or VR, is likely to witness greater adoption in the immediate future? § How have big pharma players used AR / VR to create interactive and immersive experiences for their consumers? § Which companies are potential strategic partners for AR / VR based digital marketing service providers? § What are the factors that are likely to influence the evolution of this market? § How is the current and future opportunity likely to be distributed across key market segments? The USD 3.04 billion (by 2030) financial opportunity within the AR / VR based healthcare digital marketing service providers market has been analyzed across the following segments: § Type of Technology AR Based Services MR Based Services VR Based Services § Type of product Hardware Software § End-User Large Companies Small and Mid-sized Companies To request for customize Report - https://www.rootsanalysis.com/reports/healthcare-digital-marketing/request-customization.html § Key Geographical Regions North America Europe Asia-Pacific Rest of the World The report features inputs from eminent industry stakeholders, according to whom, a significant increase in adoption of AR / VR based digital marketing services is anticipated in pharmaceutical industry, in the foreseen future. The report includes detailed transcripts of the discussions held with the following experts: § Dhananjay Arora (CEO, Kwebmaker) § Pritam Sahu (Director, Unanimity Information & Technology) The research includes detailed profiles of key players engaged in this domain; each profile features an overview of the company, recent developments and an informed future outlook. § ARWorks § CG Life § CubeZoo § Impact XM § INVIVO Communications § Mirum § Pixacore § Random42 § Quast Media § Tipping Point Media § vStream For additional details, please visit https://www.rootsanalysis.com/reports/view_document/healthcare-digital-marketing/323.html You may also be interested in the following titles: 1. Global Collaborative Robots (Cobots) Market, 2020-2030 2. Digital Health Marketv: Focus on Digital Therapeutics (2nd Edition), 2020-2030 3. Digital Twin Market: Global Opportunity and Trend Analysis, 2020-2035 4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 5. Synthetic Lethality-based Drugs and Targets Market, 2019-2030 6. Microneedles and Needle-Free Injection Systems About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis
  5. Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings. Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html Key Market Insights Over 100 CMOs presently claim to offer manufacturing services for antibodies The antibody contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial). More than 90% service providers are focused on the production of monoclonal antibodies However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments. Europe has emerged as a key manufacturing hub for antibody-based products More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan. More than 90 partnership agreements have been inked between 2013 and 2019 Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%). Multiple expansion initiatives were undertaken by CMOs between 2017 and 2019 More than 50% of such initiatives were reported to be focused on the expansion of manufacturing facilities, followed by building new facilities (38%). It is worth noting that close to 50% of the total number of expansion initiatives were undertaken in Europe, of which, 25% were in the UK. Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025 Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand. Across the three major global regions, North America represent over half of the overall global manufacturing demand for antibodies. North America and Europe are anticipated to capture over 70% of the market share by 2030 However, the market in the Asia is anticipated to grow at a relatively faster rate. Further, presently, more than 90% of the antibodies are being developed using mammalian expression systems, and this trend is unlikely to change significantly in short to mid-term. To request a sample report - https://www.rootsanalysis.com/reports/295/request-sample.html Key Questions Answered § Who are the leading CMOs engaged in the production of antibody-based therapeutics? § What kind of partnership models are commonly adopted by stakeholders in this industry? § What is the annual clinical and commercial demand for antibody-based products? § What is the current installed capacity for manufacturing of antibodies? § What are the various expansion initiatives undertaken by antibody CMOs? § How is the current and future market opportunity likely to be distributed across key market segments? The USD 17 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments: § Type of Antibodies § Monoclonal Antibodies § Bispecific Antibodies § ADCs § Others § Company Size § Small § Mid-sized § Large / Very Large § Scale of Operation § Preclinical / Clinical § Commercial § Type of expression system used § Mammalian § Microbial § Key geographical regions § North America § Europe § Asia and RoW The report features inputs from eminent industry stakeholders, according to whom antibody therapeutics developers are increasingly outsourcing their manufacturing operations owing to complex nature of the overall process, as well as the high investments associated with setting-up in-house expertise. The report includes detailed transcripts of discussions held with the following experts: § Dietmar Katinger (Chief Executive Officer, Polymun Scientific) § David C Cunningham (Director, Corporate Development, Goodwin Biotechnology) § Claire Otjes (Marketing Manager, Batavia Biosciences) The research covers profiles of key players that offer manufacturing services for antibodies, featuring a company overview, information on their respective service portfolios, manufacturing facilities and capabilities, and an informed future outlook. § AGC Biologics § Aldevron § AMRI § Boehringer Ingelheim BioXcellence § Emergent BioSolutions § Eurofins CDMO § FUJIFILM Diosynth Biotechnologies § KBI Biopharma § Lonza § Nitto Avecia Pharma Services § Novasep § Pierre Fabre § Samsung BioLogics § Synthon § Thermo Fisher Scientific To request a customize report - https://www.rootsanalysis.com/reports/antibody-cmo-market/request-customization.html You may also be interested in the following titles: 1. Bispecific Antibody Therapeutics Market 2. Antibody Drug Conjugates (ADCs) 3. Antibody Drug Conjugates Market 4. Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market 5. Dravet Syndrome Market 6. Alpha-1 Antitrypsin Deficiency (AATD) Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 gaurav.chaudhary@rootsanalysis.com
  6. Off-site, modular construction minimizes disruption to building timelines and logistical delays, ensuring systematic delivery of new facilities, this is particularly beneficial within the healthcare industry, where speed, sanitation and sterility are crucial Roots Analysis is pleased to announce the publication of its recent study, titled, “Modular Facilities in Pharmaceutical and Biotechnology Market” The report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features: § An in-depth review of the market landscape of players that offer services for modular facility construction for biotechnology and pharmaceutical industries, along with the details of certifications obtained and COVID-19 related initiatives undertaken by modular service providers. § A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size, location of headquarters, type of industry served, type of modular cleanrooms, type of modular cleanroom components. It also includes details related to regulatory approvals and certifications. § An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021. § An in-depth analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. § An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players. § Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. § An in-depth review of emerging trends, including processing technologies with modular facilities, the shift towards smaller, multi-purpose modular facilities, and technological advancements in modular construction processes. § A detailed discussion on the various growth drivers and trends related to modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs. § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) To Request Sample Pages - https://www.rootsanalysis.com/reports/178/request-sample.html § Type of Modular Construct § Hybrid Skid § Plug-and-Play § Skid-Mounted § Truckable § Others § Type of Construction Component § Base Building § Electrical System § Mechanical System § Process Equipment § Process Piping § Process Utilities § Other Components § Purpose of Facility § Aseptic Filling § Manufacturing § Research and Development § Others § Facility Area § Very Small § Small § Mid-Sized § Large § Very Large § Scale of Operation § Clinical § Commercial § Type of Industry § Pharmaceutical § Biotechnology § Type of Product § Biosimilars § Cell and Gene Therapies § Monoclonal Antibodies § Vaccines § Other Products § Type of Facility § New Facility § Facility Expansions § Key Geographical Regions § North America § Europe § Asia § Middle East and North Africa § Latin America § Rest of the World Download Free Insights now - https://www.rootsanalysis.com/reports/178/free-insights.html Transcripts of interviews held with the following senior level representatives of stakeholder companies Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction) § François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte) § Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing) § Pär Almhem (President, Modwave) § Sulogna Roy (Ex Sales Manager, Zeton) § Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation) Key companies covered in the report § Cytiva § G-CON Manufacturing § Pharmadule Morimatsu § NNE § IPM Technologies § KeyPlants § Germfree Laboratories § ModuleCO Pharma For more information, please click on the following link https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html You may also be interested in the following titles: 1. Vaccine Contract Manufacturing Market (3rd Edition) 2. Biopharmaceutical CROs Market 3. Continuous Manufacturing Equipment Providers Market, 4. DNA-Encoded Libraries 5. Deep Learning Market 6. Human Factors Engineering and Usability Testing Services Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  7. Besides portability, handheld X-ray scanners offer a wide range of benefits, including cost savings; in the initial days of the pandemic, such devices were instrumental in increasing diagnostic throughput since they could be easily sterilized Roots Analysis has announced the addition of “Global Handheld X-Ray Imaging Devices Market by Area of Application (Dental and Others), Device Class (Low-End, Mid-End and High-End), End-Users (Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, Specialty Clinics and Others), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle-East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” report to its list of offerings. The applications of handheld imaging devices in modern healthcare are vast, spanning almost all major medical disciplines, from dentistry to cardiology, covering several internal organs across various parts of the body, such as the chest, and abdomen / gastrointestinal tract. In this context, it is worth mentioning that over the past couple of months, multiple studies have described the use of handheld X-ray devices in diagnosing symptoms of the novel coronavirus infection in patients, worldwide. To order this 140+ page report, which features 70+ figures and 75+ tables, please visit this - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market.html Key Market Insights More than 50 handheld X-ray imaging devices are presently available / under development Close to 95% of the aforementioned scanners are presently being used in the field of dentistry. Some of the available devices are considered highly efficient; 35% of the products mentioned in the report can be operated over 400 times in a single charge. Such solutions are particularly beneficial in remote areas, where electricity is not easily available. Close to 85% of scanners are designed to use lithium-ion polymer batteries Prominent examples of such devices that use with lithium-ion polymer-based batteries include the Cocoon (DX7017/DX7020) Portable Handheld Dental X-Ray (Dexcowin), MaxRay Cocoon Handheld Dental X-Ray (MasterLink), NOMAD Pro 2 Handheld X-Ray System (KaVo Kerr), and Port-X IV (Genoray). 35 companies claim to be actively involved in manufacturing handheld X-ray devices Majority (76%) of the scanners mentioned in the report, are being developed by very small and small firms, followed by mid-sized (12%) and large players (12%). Interestingly, the prominent contributors in the market (26%) were observed to have been incorporated as business entities post-2015. Handheld X-ray scanners are estimated to enhance radiologists’ efficiency by ~50% Given their light-weight, and low exposure time (to harmful radiations), coupled to advances in battery chemistries that have improved efficiency, such portable diagnostic devices allow radiologists to perform more scans in a day, than what was possible using conventional X-ray equipment. In fact, by 2030, it is estimated that the aforementioned increase in productivity is likely to result in USD 11 billion worth of cost savings, when compared to using conventional devices. By 2030, diagnostic imaging centers and hospitals are anticipated to occupy over 65% of the market opportunity Given the ease in portability and higher adoption rates, the market for diagnostic imaging center is anticipated to rise at a relatively faster rate (12.94%). This is closely followed by ambulatory surgical centers (12.91%) and specialty clinics (12.74%). To Request Sample Page - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-sample.html Key Questions Answered § Who are the leading developers of handheld X-ray imaging devices? § What are the key areas of application of handheld X-ray imaging devices? § What is the relevance of X-rays in screening patients who are suspected to be infected with the novel coronavirus? § What are the likely cost saving opportunities associated with the use of handheld X-ray imaging devices? § What are the key factors influencing the adoption of handheld X-ray imaging scanners, among different end-users? § How is the current and future opportunity likely to be distributed across key market segments? § What is the impact of the COVID-19 pandemic on the handheld X-ray imaging devices market? The USD 2.8 billion (by 2030) financial opportunity within the handheld X-ray imaging devices market has been analyzed across the following segments: § Area of Application Dental Others § Device Class Low-End Mid-End High-End § End-Users Ambulatory Surgical Centers Diagnostic Imaging Centers Hospitals Specialty Clinics Other End-Users § Key Geographical Regions North America Europe Asia-Pacific Middle-East and North Africa Latin America Rest of the World Download Free Insights now - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/free-insights.html The research include brief profiles of key players engaged in the development of handheld X-ray imaging devices; other popular industry players featured in the report include: § Elidental Technology § Fujifilm § VATECH § Digimed § Digital Doc § Iatome Electric § Micro C Imaging § Nanoray § Posdion § Remedi § Seeddent § SUNUP § Video Dental Concepts § Zhengzhou Senmy Dental Equipment Request for Customize Report - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-customization.html You may also be interested in the following titles: 1. Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 2. Medical Device Batteries: 3. Pharmaceutical Contract Research Services Market 4. Cell Therapy Packaging Products and Services Market 5. Hydrogen Energy Storage Market Global Trend 6. Facial Recognition Solutions Market Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
  8. Besides portability, handheld X-ray scanners offer a wide range of benefits, including cost savings; in the initial days of the pandemic, such devices were instrumental in increasing diagnostic throughput since they could be easily sterilized Roots Analysis has announced the addition of “Global Handheld X-Ray Imaging Devices Market by Area of Application (Dental and Others), Device Class (Low-End, Mid-End and High-End), End-Users (Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, Specialty Clinics and Others), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle-East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” report to its list of offerings. The applications of handheld imaging devices in modern healthcare are vast, spanning almost all major medical disciplines, from dentistry to cardiology, covering several internal organs across various parts of the body, such as the chest, and abdomen / gastrointestinal tract. In this context, it is worth mentioning that over the past couple of months, multiple studies have described the use of handheld X-ray devices in diagnosing symptoms of the novel coronavirus infection in patients, worldwide. To order this 140+ page report, which features 70+ figures and 75+ tables, please visit this - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market.html Key Market Insights More than 50 handheld X-ray imaging devices are presently available / under development Close to 95% of the aforementioned scanners are presently being used in the field of dentistry. Some of the available devices are considered highly efficient; 35% of the products mentioned in the report can be operated over 400 times in a single charge. Such solutions are particularly beneficial in remote areas, where electricity is not easily available. Close to 85% of scanners are designed to use lithium-ion polymer batteries Prominent examples of such devices that use with lithium-ion polymer-based batteries include the Cocoon (DX7017/DX7020) Portable Handheld Dental X-Ray (Dexcowin), MaxRay Cocoon Handheld Dental X-Ray (MasterLink), NOMAD Pro 2 Handheld X-Ray System (KaVo Kerr), and Port-X IV (Genoray). 35 companies claim to be actively involved in manufacturing handheld X-ray devices Majority (76%) of the scanners mentioned in the report, are being developed by very small and small firms, followed by mid-sized (12%) and large players (12%). Interestingly, the prominent contributors in the market (26%) were observed to have been incorporated as business entities post-2015. Handheld X-ray scanners are estimated to enhance radiologists’ efficiency by ~50% Given their light-weight, and low exposure time (to harmful radiations), coupled to advances in battery chemistries that have improved efficiency, such portable diagnostic devices allow radiologists to perform more scans in a day, than what was possible using conventional X-ray equipment. In fact, by 2030, it is estimated that the aforementioned increase in productivity is likely to result in USD 11 billion worth of cost savings, when compared to using conventional devices. By 2030, diagnostic imaging centers and hospitals are anticipated to occupy over 65% of the market opportunity Given the ease in portability and higher adoption rates, the market for diagnostic imaging center is anticipated to rise at a relatively faster rate (12.94%). This is closely followed by ambulatory surgical centers (12.91%) and specialty clinics (12.74%). To Request Sample Page - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-sample.html Key Questions Answered § Who are the leading developers of handheld X-ray imaging devices? § What are the key areas of application of handheld X-ray imaging devices? § What is the relevance of X-rays in screening patients who are suspected to be infected with the novel coronavirus? § What are the likely cost saving opportunities associated with the use of handheld X-ray imaging devices? § What are the key factors influencing the adoption of handheld X-ray imaging scanners, among different end-users? § How is the current and future opportunity likely to be distributed across key market segments? § What is the impact of the COVID-19 pandemic on the handheld X-ray imaging devices market? The USD 2.8 billion (by 2030) financial opportunity within the handheld X-ray imaging devices market has been analyzed across the following segments: § Area of Application Dental Others § Device Class Low-End Mid-End High-End § End-Users Ambulatory Surgical Centers Diagnostic Imaging Centers Hospitals Specialty Clinics Other End-Users § Key Geographical Regions North America Europe Asia-Pacific Middle-East and North Africa Latin America Rest of the World Download Free Insights now - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/free-insights.html The research include brief profiles of key players engaged in the development of handheld X-ray imaging devices; other popular industry players featured in the report include: § Elidental Technology § Fujifilm § VATECH § Digimed § Digital Doc § Iatome Electric § Micro C Imaging § Nanoray § Posdion § Remedi § Seeddent § SUNUP § Video Dental Concepts § Zhengzhou Senmy Dental Equipment Request for Customize Report - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-customization.html You may also be interested in the following titles: 1. Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 2. Medical Device Batteries: 3. Pharmaceutical Contract Research Services Market 4. Cell Therapy Packaging Products and Services Market 5. Hydrogen Energy Storage Market Global Trend 6. Facial Recognition Solutions Market Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
  9. Off-site, modular construction minimizes disruption to building timelines and logistical delays, ensuring systematic delivery of new facilities, this is particularly beneficial within the healthcare industry, where speed, sanitation and sterility are crucial Roots Analysis is pleased to announce the publication of its recent study, titled, “Modular Facilities in Pharmaceutical and Biotechnology Market” The report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features: § An in-depth review of the market landscape of players that offer services for modular facility construction for biotechnology and pharmaceutical industries, along with the details of certifications obtained and COVID-19 related initiatives undertaken by modular service providers. § A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size, location of headquarters, type of industry served, type of modular cleanrooms, type of modular cleanroom components. It also includes details related to regulatory approvals and certifications. § An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021. § An in-depth analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. § An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players. § Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. § An in-depth review of emerging trends, including processing technologies with modular facilities, the shift towards smaller, multi-purpose modular facilities, and technological advancements in modular construction processes. § A detailed discussion on the various growth drivers and trends related to modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs. § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) To Request Sample Pages - https://www.rootsanalysis.com/reports/178/request-sample.html § Type of Modular Construct § Hybrid Skid § Plug-and-Play § Skid-Mounted § Truckable § Others § Type of Construction Component § Base Building § Electrical System § Mechanical System § Process Equipment § Process Piping § Process Utilities § Other Components § Purpose of Facility § Aseptic Filling § Manufacturing § Research and Development § Others § Facility Area § Very Small § Small § Mid-Sized § Large § Very Large § Scale of Operation § Clinical § Commercial § Type of Industry § Pharmaceutical § Biotechnology § Type of Product § Biosimilars § Cell and Gene Therapies § Monoclonal Antibodies § Vaccines § Other Products § Type of Facility § New Facility § Facility Expansions § Key Geographical Regions § North America § Europe § Asia § Middle East and North Africa § Latin America § Rest of the World Download Free Insights now - https://www.rootsanalysis.com/reports/178/free-insights.html Transcripts of interviews held with the following senior level representatives of stakeholder companies Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction) § François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte) § Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing) § Pär Almhem (President, Modwave) § Sulogna Roy (Ex Sales Manager, Zeton) § Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation) Key companies covered in the report § Cytiva § G-CON Manufacturing § Pharmadule Morimatsu § NNE § IPM Technologies § KeyPlants § Germfree Laboratories § ModuleCO Pharma For more information, please click on the following link https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html You may also be interested in the following titles: 1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030 2. Biopharmaceutical CROs Market, 2021-2030 3. Continuous Manufacturing Equipment Providers Market, 2021-2030 4. DNA-Encoded Libraries: Platforms and Services Market 5. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  10. To order this 140+ page report, please visit this - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market.html Key Inclusions § An overview of the current market landscape of the handheld X-ray imaging devices, providing information on the status of development (developed and under development), area of application (dental, orthopedic and others), weight of device, size of focal spot, tube voltage, type of battery used (lithium ion and lithium polymer), battery voltage, exposure time, battery efficiency and cost of the device. In addition, it presents details of the device developers, highlighting their respective year of establishment, company size, type of business model used (B2B and B2C), target market (domestic and domestic and international) and location of headquarters. § An in-depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a grid representation, illustrating the distribution of devices based on weight of the device, area of application and size of the company, [B] an insightful heat map representation, highlighting the distribution of devices on the basis of weight and cost of the device, [C] a treemap representation, featuring the distribution of handheld X-ray imaging devices based on battery efficiency and exposure time, and [D] a world map representation, highlighting the regional distribution of developer companies. § A detailed product competitiveness analysis of handheld X-ray imaging devices, taking into consideration several relevant parameters, such as the supplier power (based on year of establishment of the developer) and key device-related specifications, including device weight, size of focal spot, type of battery, battery efficiency, minimum exposure time and product price. § Elaborate profiles of mid-sized / large companies (based on a proprietary shortlisting criteria) that are engaged in the development of handheld X-ray imaging devices. Each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook. § A detailed brand positioning analysis of key industry players (based on a proprietary shortlisting criteria), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength of product portfolio, diversity in battery efficiency, diversity in exposure time, cost of the device and supplier power of each company. § An insightful analysis highlighting the cost saving potential associated with the use of handheld X-ray imaging devices, based on the information from over 30 countries, taking into consideration various parameters, such as total number of radiologists, annual salary, number of X-ray scans performed and increase in efficiency by adoption of these handheld X-ray imaging devices. § A review of the product distribution strategies adopted by different end-users and market attractiveness for handheld X-ray imaging devices across different types of end-users, including ambulatory surgical centers, diagnostic imaging centers, hospitals, specialty clinics and others. § A discussion on the impact of COVID-19 pandemic on the overall handheld X-ray imaging devices market, and the key initiatives undertaken by the companies in this domain. § An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till October) and insights from recent news articles related to handheld X-ray imaging devices, indicating the increasing popularity of this domain To Request Sample Page - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-sample.html The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: § Area of Application Dental Others § Device Class Low-End Mid-End High-End § End-Users Ambulatory Surgical Centers Diagnostic Imaging Centers Hospitals Specialty Clinics Other End-Users § Key Geographical Regions North America Europe Asia-Pacific Middle-East and North Africa Latin America Rest of the World To request sample pages, please visit this - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-sample.html Key Questions Answered § Who are the leading developers of handheld X-ray imaging devices? § What are the key areas of application of handheld X-ray imaging devices? § What is the relevance of X-rays in screening patients who are suspected to be infected with the novel coronavirus? § What are the likely cost saving opportunities associated with the use of handheld X-ray imaging devices? § What are the key factors influencing the adoption of handheld X-ray imaging scanners, among different end-users? § How is the current and future opportunity likely to be distributed across key market segments? § What is the impact of the COVID-19 pandemic on the handheld X-ray imaging devices market? You may also be interested in the following titles: 1. Global Handheld Ultrasound Imaging Devices 2. Medical Device Batteries: 3. Point-of-Care Diagnostics Market 4. Global Handheld Ultrasound Imaging Devices Market, 2020-2030 5. Medical Device Batteries: Focus on Implants and Wearable Medical Devices - 6. Point-of-Care Diagnostics Market for Infectious Diseases by Indication Contact Us Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  11. Roots Analysis has done a detailed study on “Global Handheld X-Ray Imaging Devices Market by Area of Application (Dental and Others), Device Class (Low-End, Mid-End and High-End), End-Users (Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, Specialty Clinics and Others), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle-East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 140+ page report, which features 70+ figures and 75+ tables, please visit this - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market.html Key Market Insights § Several players are currently engaged in the development / manufacturing of handheld X-ray imaging devices of the different classes; these modalities hold applications in quick patient diagnosis, even at remote locations § Over 50 such point-of-care devices, with several advanced features, have been developed, enabling a significant reduction in the global diagnostic imaging burden. § Stakeholders have established strong brand positions in different geographies; in future, such companies are anticipated to contribute the most to the overall revenue generation potential. § In the pursuit of building a competitive edge, device, developers are focusing on the integration of advanced features into their respective product and affiliated offerings. § Due to their compact size, minimal radiation exposure, and enhanced battery efficiency, these solutions can significantly enhance a radiologist’s efficiency, demonstrating the potential to save healthcare cost. § Driven by the rising need for easily portable devices, the market is poised to grow at a CAGR of over 12% till 2030; we expect the opportunity to be well distributed across key market segments. For more information, please visit https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market.html Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Key Questions Answered 1.4. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Introduction to X-Ray Imaging 3.3. Historical Evolution of X-Ray Imaging 3.4. Key Challenges Associated with Conventional X-Ray Imaging Devices 3.5. Portable X-Ray Imaging Devices 3.5.1. Device Classification 3.5.1.1. Cart based / Mobile X-Ray Imaging Devices 3.5.1.2. Handheld X-Ray Imaging Devices 3.5.2. Key Areas of Application 3.5.3. Key Advantages and Limitations 3.6. Prevalent Trends Related to Handheld X-Ray Imaging Devices 3.6.1. Emerging Focus Areas 3.6.2. Key Historical Trends 3.6.3. Geographical Activity 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Handheld X-Ray Imaging Devices: Overall Market Landscape 4.2.1. Analysis by Status of Development 4.2.2. Analysis by Area of Application 4.2.3. Analysis by Weight of Device 4.2.4. Analysis by Size of Focal Spot 4.2.5. Analysis by Tube Voltage 4.2.6. Analysis by Type of Battery Used 4.2.7. Analysis by Battery Voltage 4.2.8. Analysis by Battery Efficiency 4.2.9. Analysis by Minimum Exposure Time 4.2.10. Analysis by Cost of Device 4.3. Handheld X-Ray Imaging Devices: Information on Affiliated Technologies 4.4. Handheld X-Ray Imaging Devices: Developer Landscape 4.4.1. Analysis by Year of Establishment 4.4.2. Analysis by Company Size 4.4.3. Analysis by Types of Business Model Used 4.4.4. Analysis by Target Market 4.4.5. Analysis by Location of Headquarters 4.4.6. Leading Manufacturers: Analysis by Number of Products 4.5. Grid Representation: Analysis by Area of Application, Weight of Device and Company Size 4.6. Heat Map Representation: Analysis by Weight and Cost of Device 4.7. Treemap Representation: Analysis by Battery Efficiency and Exposure Time 4.8. World Map Representation: Regional Activity 5. PRODUCT COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Methodology 5.3. Assumptions / Key Parameters 5.4. Product Competitiveness Analysis 5.4.1. Product Competitiveness Analysis: Low-End Devices 5.4.2. Product Competitiveness Analysis: Mid-End Devices 5.4.3. Product Competitiveness Analysis: High-End Devices 5.4.4. Product Competitiveness Analysis: Other Devices To Request Sample Page - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-sample.html 6. COMPANY PROFILES 6.1. Chapter Overview 6.2. Dexcowin 6.2.1. Company Overview 6.2.2. Handheld X-Ray Imaging Device Portfolio 6.2.3. Recent Developments and Future Outlook 6.3. Elidental Technology 6.3.1. Company Overview 6.3.2. Handheld X-Ray Imaging Device Portfolio 6.3.3. Recent Developments and Future Outlook 6.4. Fujifilm 6.4.1. Company Overview 6.4.2. Handheld X-Ray Imaging Device Portfolio 6.4.3. Recent Developments and Future Outlook 6.5. Genoray 6.5.1. Company Overview 6.5.2. Handheld X-Ray Imaging Device Portfolio 6.5.3. Recent Developments and Future Outlook 6.6. KaVo Kerr 6.6.1. Company Overview 6.6.2. Handheld X-Ray Imaging Device Portfolio 6.6.3. Recent Developments and Future Outlook 6.7. VATECH 6.7.1. Company Overview 6.7.2. Handheld X-Ray Imaging Device Portfolio 6.7.3. Recent Developments and Future Outlook 7. BRAND POSITIONING ANALYSIS OF KEY PLAYERS 7.1. Chapter Overview 7.2. Key Parameters and Methodology 7.3. Brand Positioning Matrix: Dexcowin 7.4. Brand Positioning Matrix: Elidental Technology 7.5. Brand Positioning Matrix: Fujifilm 7.6. Brand Positioning Matrix: Genoray 7.7. Brand Positioning Matrix: KaVo Kerr 7.8. Brand Positioning Matrix: VATECH 8. COST SAVING ANALYSIS 8.1. Chapter Overview 8.2. Key Assumptions and Methodology 8.3. Key Parameters Influencing the Cost of Handheld X-Ray Imaging Devices 8.4. Overall Cost Saving Potential of Handheld X-Ray Imaging Devices, 2020-2030 8.5. Cost Saving Potential of Handheld X-Ray Imaging Devices: Analysis by Geography 8.5.1. Cost Saving Potential of Handheld X-Ray Imaging Devices in North America, 2020-2030 8.5.2. Cost Saving Potential of Handheld X-Ray Imaging Devices in Europe, 2020-2030 8.5.3. Cost Saving Potential of Handheld X-Ray Imaging Devices in Asia-Pacific, 2020-2030 8.6. Cost Saving Potential of Handheld X-Ray Imaging Devices: Analysis by Economic Strength 8.6.1. Cost Saving Potential of Handheld X-Ray Imaging Devices in High Income Countries, 2020-2030 8.6.2. Cost Saving Potential of Handheld X-Ray Imaging Devices in Middle Income Countries, 2020-2030 8.7. Concluding Remarks: Cost Saving Scenarios 9. MARKET FORECAST 9.1. Chapter Overview 9.2. Forecast Methodology and Key Assumptions 9.3. Overall Handheld X-Ray Imaging Devices Market, 2020-2030 9.3.1. Handheld X-Ray Imaging Devices Market: Distribution by Area of Application 9.3.1.1. Handheld X-Ray Imaging Devices Market for Dental Scans, 2020-2030 9.3.1.2. Handheld X-Ray Imaging Devices Market for Other Areas of Application, 2020-2030 9.3.2. Handheld X-Ray Imaging Devices Market: Distribution by Device Class 9.3.2.1. Handheld X-Ray Imaging Devices Market for Low-End Devices, 2020-2030 9.3.2.2. Handheld X-Ray Imaging Devices Market for Mid-End Devices, 2020-2030 9.3.2.3. Handheld X-Ray Imaging Devices Market for High-End Devices, 2020-2030 9.3.3. Handheld X-Ray Imaging Devices Market: Distribution by End-Users 9.3.4. Handheld X-Ray Imaging Devices Market: Distribution by Key Geographical Regions 9.3.4.1. Handheld X-Ray Imaging Devices Market in North America, 2020-2030 9.3.4.2. Handheld X-Ray Imaging Devices Market in Europe, 2020-2030 9.3.4.3. Handheld X-Ray Imaging Devices Market in Asia-Pacific, 2020-2030 9.3.4.4. Handheld X-Ray Imaging Devices Market in Middle-East and North Africa, 2020-2030 9.3.4.5. Handheld X-Ray Imaging Devices Market in Latin America, 2020-2030 9.3.4.6. Handheld X-Ray Imaging Devices Market in Rest of the World, 2020-2030 10. MARKET OPPORTUNITY ANALYSIS (END-USERS PERSPECTIVE) 10.1. Chapter Overview 10.2. Methodology 10.3. Distribution / Marketing Strategies Adopted by Device Developers 10.4. Market Attractiveness Analysis 10.4.1. End-User Market Attractiveness: Ambulatory Surgical Centers, 2020-2030 10.4.2. End-User Market Attractiveness: Diagnostic Imaging Centers, 2020-2030 10.4.3. End-User Market Attractiveness: Hospitals, 2020-2030 10.4.4. End-User Market Attractiveness: Specialty Clinics, 2020-2030 10.4.5. End-User Market Attractiveness: Other End-Users, 2020-2030 11. CASE STUDY: IMPACT OF COVID-19 PANDEMIC 11.1. Chapter Overview 11.2. Impact of COVID-19 Pandemic on Diagnostic Imaging 11.2.1. Impact on Future Market Opportunity for Handheld X-Ray Imaging Devices Market 11.3. Recuperative Strategies for Developer Business 11.3.1. Strategies for Implementation in Short / Mid-Term 11.3.2. Strategies for Implementation in the Long-Term 12. CONCLUSION 13. APPENDIX I: TABULATED DATA 14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS 15. APPENDIX III: LIST OF DISTRIBUTORS / SUPPLIERS Download Free Insights now - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/free-insights.html You may also be interested in the following titles: 1. Global Handheld Ultrasound Imaging Devices 2. Medical Device Batteries: 3. Point-of-Care Diagnostics Market 4. Global Handheld Ultrasound Imaging Devices Market, 2020-2030 5. Medical Device Batteries: Focus on Implants and Wearable Medical Devices - 6. Point-of-Care Diagnostics Market for Infectious Diseases by Indication Contact Details Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  12. The growing realization of the importance of early diagnosis coupled to technical advances in digital radiography, have led to the development and widespread adoption of handheld X-ray scanners, revolutionizing modern diagnostic imaging. Roots Analysis is pleased to announce the publication of its recent study titled, “Global Handheld X-Ray Imaging Devices Market by Area of Application (Dental and Others), Device Class (Low-End, Mid-End and High-End), End-Users (Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, Specialty Clinics and Others), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle-East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2020-2030”. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these devices over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes: § A detailed assessment of the current market landscape of companies engaged in the development of handheld x-ray imaging devices. § An in-depth analysis of contemporary market trends for the most popular devices taking into consideration the strength of product portfolio and key product specific parameters. § An insightful product competitiveness analysis of handheld X-ray imaging devices featuring developer’s specifications device related features. § Elaborate profiles of developers that are engaged in the development of handheld X-ray imaging devices. (shortlisted based on the number of pipeline devices). § A detailed brand positioning analysis of key industry players highlighting the current perceptions regarding their proprietary brands based on aspects like strength of product portfolio, diversity in battery efficiency, diversity in exposure time, cost of the device and supplier power of each company. § A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary brands based on device specifications. § A review of the product distribution strategies adopted by different end-users and market attractiveness for handheld X-ray imaging devices across different types of end-users. § An insightful discussion on the impact of COVID-19 pandemic on the overall and held X-ray imaging devices market and the key initiatives undertaken by companies. § An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till October) and insights from recent news articles related to handheld X-ray imaging devices, indicating the increasing popularity of this domain. § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Download Free Insights now - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/free-insights.html § Area of Application Dental § Others § Device Class Low-End Mid-End High-End § End-Users Ambulatory Surgical Centers Diagnostic Imaging Centers Hospitals Specialty Clinics Other End-Users § Key Geographical Regions North America Europe Asia-Pacific Middle-East and North Africa Latin America Rest of the World To Request Sample Page - https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market/request-sample.html Key companies covered in the report § Elidental Technology § Fujifilm § VATECH § Digimed § Digital Doc § Iatome Electric § Micro C Imaging § Nanoray § Posdion § Remedi § Seeddent § SUNUP § Video Dental Concepts § Zhengzhou Senmy Dental Equipment For more information, please click on the following link: https://www.rootsanalysis.com/reports/handheld-x-ray-imaging-devices-market.html You may also be interested in the following titles: 1. Global Handheld Ultrasound Imaging Devices 2. Medical Device Batteries: 3. Point-of-Care Diagnostics Market 4. Global Handheld Ultrasound Imaging Devices Market, 2020-2030 5. Medical Device Batteries: Focus on Implants and Wearable Medical Devices - 6. Point-of-Care Diagnostics Market for Infectious Diseases by Indication About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  13. Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” The report features an extensive study of the contract services market for ophthalmic products and solutions. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes: § A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters. § A competitiveness analysis of prominent contract manufacturers, featuring insightful pictorial summaries and representations. § Elaborate profiles of key players that offer a diverse range of capabilities for the contract development, manufacturing and packaging of ophthalmic drug products. § A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products. § An estimate of the overall, annual capacity for manufacturing ophthalmic APIs and drug FDFs based on data reported by industry stakeholders in the public domain. § An informed estimate of the annual clinical and commercial demand for ophthalmic APIs and drug FDFs. § A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, including a Harvey ball analysis highlighting the relative effect of each SWOT parameter on the overall industry. § A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to ophthalmic drug developers. § A discussion on the emerging trends and potential market drivers, which are likely to impact the evolution of the market in the coming years. § A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on a number of relevant parameters. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) § Type of product § Ophthalmic API § Ophthalmic drug FDF § Type of FDF manufactured § Solid § Semi-solid § Liquid / suspension § Type of primary packaging § Ampoule / vial § Glass / plastic bottle § Ointment tube § Blister packing § Other forms § Scale of manufacturing § Clinical § Commercial § Company size § Small § Mid-sized § Large § Very large § Target disease indication § Age-related macular degeneration § Dry eye § Glaucoma § Other disease segments § Key geographical regions § North America (US, Canada and Mexico) § Europe (UK, Germany, France, Spain, Italy and rest of Europe) § Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific) § Rest of the world Key companies covered in the report § Akorn § Akums § Bal Pharma § Catalent § Cayman Chemical § Entod Pharmaceuticals § Farmigea § Glenmark Pharmaceuticals § Indiana Ophthalmics § Lomapharm § Medichem § Pillar5 Pharma § Recipharm § Salvat § Sterling Pharmaceutical Services § Sunways India For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html Other Recent Offerings China Biopharmaceutical Contract Manufacturing Market, 2020-2030 Pharmaceutical Continuous Manufacturing Market, 2020-2030 Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
  14. To order this 375+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html Key Inclusions § A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications. § A company competitiveness analysis, highlighting prominent ophthalmic drug contract manufacturers based on supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications).. § Elaborate profiles of key players based in North America, Europe and Asia-Pacific that offer a diverse range of capabilities for the development, manufacturing and packaging of ophthalmic drug products. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook. § A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted). § An informed estimate of the annual commercial demand for ophthalmic APIs and drug FDFs (in million litres), taking into account the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account ongoing and planned clinical trials. § A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, based on data gathered via secondary and primary research. It also provides the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific). § A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry. § A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to ophthalmic drug developers. § A discussion on the emerging trends and potential market drivers, such as the growing ophthalmic drugs / therapies pipeline, rise in outsourcing activity for sterile manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years. § A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: § Type of product § Ophthalmic API § Ophthalmic drug FDF § Type of FDF manufactured § Solid § Semi-solid § Liquid / suspension § Type of primary packaging § Ampoule / vial § Glass / plastic bottle § Ointment tube § Blister packing § Other forms § Scale of manufacturing § Clinical § Commercial § Company size § Small § Mid-sized § Large § Very large § Target disease indication § Age-related macular degeneration § Dry eye § Glaucoma § Other disease segments § Key geographical regions § North America (US, Canada and Mexico) § Europe (UK, Germany, France, Spain, Italy and rest of Europe) § Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific) § Rest of the world To request a sample copy / brochure, please visit this - https://www.rootsanalysis.com/reports/294/request-sample.html Key Questions Answered § What is the clinical research landscape of investigational ophthalmic drugs? § What percentage of ophthalmic drug manufacturing operations are outsourced to service providers? § What are the preferred primary packaging formats / fill finish containers of ophthalmic drugs? § Who are the leading contract manufacturers of ophthalmic APIs and drug FDFs, across the globe? § What are the key challenges faced by ophthalmic drug contract manufacturers? § What is the annual, clinical and commercial demand for ophthalmic drugs? § What is the current, installed manufacturing capacity for ophthalmic drugs? § What are the anticipated future trends related to ophthalmic drug manufacturing? § How is the current and future market opportunity likely to be distributed across key market segments? You may also be interested in the following titles: 1. China Biopharmaceutical Contract Manufacturing Market, 2020-2030 2. Pharmaceutical Continuous Manufacturing Market, 2020-2030 3. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
  15. Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers. To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html The USD 1.7 billion financial opportunity (by 2030) within the ophthalmic drugs contract manufacturing market has been analyzed across the following segments: § Type of product § Ophthalmic API § Ophthalmic drug FDF § Type of FDF manufactured § Solid § Semi-solid § Liquid / suspension § Type of primary packaging § Ampoule / vial § Glass / plastic bottle § Ointment tube § Blister packing § Other forms § Scale of manufacturing § Clinical § Commercial § Company size § Small § Mid-sized § Large § Very large § Target disease indication § Age-related macular degeneration § Dry eye § Glaucoma § Other disease segments § Key geographical regions § North America (US, Canada and Mexico) § Europe (UK, Germany, France, Spain, Italy and rest of Europe) § Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific) § Rest of the world The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” report features the following companies, which we identified to be key players in this domain: § Akorn § Akums § Bal Pharma § Catalent § Cayman Chemical § Entod Pharmaceuticals § Farmigea § Glenmark Pharmaceuticals § Indiana Ophthalmics § Lomapharm § Medichem § Pillar5 Pharma § Recipharm § Salvat § Sterling Pharmaceutical Services § Sunways India Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape 5. Company Competitiveness Analysis 6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles 7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles 8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles 9. Clinical Trial Analysis 10. Capacity Analysis 11. Demand Analysis 12. Market Forecast 13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies 14. SWOT Analysis 15. Survey Analysis 16. Executive Insights 17. Future Growth Opportunities 18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers 19. Appendix 2: Tabulated Data 20. Appendix 3: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
  16. Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions. To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html The USD 860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments: § Type of test § Laboratory Developed Tests (LDTs) § Companion Diagnostic Tests (CDx) § Type of disease indication § Breast cancer § Blood cancer § Colon / Colorectal cancer § Lung Cancer § Melanoma § Prostate Cancer § Type of cancer biomarker § TMB § MSI / MMR § TILs § Type of analytical technique § Next Generation Sequencing (NGS) § Polymerase Chain Reaction (PCR) § Immunohistochemistry (IHC) § Others § Key geographical regions § North America § Europe § Japan § China § Australia The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.” report features the following companies, which we identified to be key players in this domain: § Foundation Medicine § NeoGenomics Laboratories § Novogene § Q2 Solutions § Personal Genome Diagnostics § Dr Lal PathLabs § Shenzhen Yuce Biotechnology Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape 5. Product Competitiveness Analysis 6. Company Profiles 7. Publication Analysis 8. Innovative Designs for Biomarker-Based Clinical Trials 9. Clinical Trial Analysis 10. Market Forecast 11. Future Growth Opportunities 12. Case Study: Analysis of Needs of Stakeholders in The Companion Diagnostics Industry 13. Case Study: Analysis of Value Chain in the Companion Diagnostics Industry 14. Clinical Research on Cancer Biomarkers: A Big Pharma Perspective 15. Executive Insights 16. Appendix 1: Tabulated Data 17. Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html Contact Details Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  17. Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.” The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes: § A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies. § An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+). § An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups). § Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio). § A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs. § A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs. § A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years. § A discussion on various steps involved in development operations of companion diagnostics § A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Type of test § Laboratory Developed Tests (LDTs) § Companion Diagnostic Tests (CDx) Type of disease indication § Breast cancer § Blood cancer § Colon / Colorectal cancer § Lung Cancer § Melanoma § Prostate Cancer Type of cancer biomarker § TMB § MSI / MMR § TILs Type of analytical technique § Next Generation Sequencing (NGS) § Polymerase Chain Reaction (PCR) § Immunohistochemistry (IHC) § Others Key geographical regions § North America § Europe § Japan § China § Australia Key companies covered in the report § Foundation Medicine § NeoGenomics Laboratories § Novogene § Q2 Solutions § Personal Genome Diagnostics § Dr Lal PathLabs § Shenzhen Yuce Biotechnology For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html Other Recent Offerings 1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030 2. Neoantigen Targeted Therapies Market, 2019-2030 3. Companion Diagnostics Market (2nd Edition), 2019-2030 4. Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030 5. In Vitro ADME Testing Services Market, 2019-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  18. Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030. The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes: § A detailed review of the current landscape of companies offering contract manufacturing services. § Elaborate profiles of key players that specialize in offering services for contract biomanufacturing. § A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations. § An analysis of the partnerships and expansions that have been established in this domain, in the recent past. § A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations. § A detailed proprietary 2×2 representation to assess the current market scenario § An analysis of the initiatives of big biopharma players engaged in this domain. § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) § Type of Product § API § FDF § Type of Biologic § Proteins § Enzymes § Growth Hormones § Antibody based Drugs § Others (plasmid DNA, probiotics, microbiome-based biologics) § Type of Microbial Expression System § Bacteria § Yeast § Others (Algae and fungi) § Scale of Operation § Commercial § Preclinical / Clinical § Type of End User § Small Companies § Mid-sized Companies § Large / Very Large Companies § Key Geographical Regions § North America § Europe § Asia Pacific § Middle East and North Africa § Latin America Transcripts of interviews held with the following senior level representatives of stakeholder companies § Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals) § Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories) § Andrea Conforto (Sales and Marketing, Bioservices Director, Olon) § Max Rossetto (General Manager, Business Development, Luina Bio) § Rob van Dijk (Business Development Manager, WACKER Biotech) Key companies covered in the report § AGC Biologics § Aldevron § BioVectra § EirGenix § Etinpro § Eurogentec § Northway Biotechpharma § Ology Bioservices § Porton Biopharma § Stelis Biopharma For additional details, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Drug Repurposing Service Providers Market, 2020 – 2030 2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030 3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
  19. The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment London Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings. Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs. To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html Key Market Insights Over 115 CMOs claim to offer manufacturing services for microbial biologics The microbial contract biomanufacturing market is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 50% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation (preclinical, clinical and commercial). Presently, more than 70% of service providers use bacterial expression systems Recently, a number of microbial biologics manufacturers are shifting to yeast-based production systems. It is also worth highlighting that close to 30% of CMOs, identified in this research, claim to have the required capabilities to manufacture biologics using both bacterial and yeast-based systems. Europe is currently regarded as a key manufacturing hub for microbial biologics There are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%). On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel. Several partnerships were established in this domain, during the period 2016-2020 Majority of the deals recorded in the report, were established in 2019. Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%). Further, multiple expansion initiatives were undertaken by CMOs, since 2016 More than 30% of expansion projects over the last few years were focused on the establishment of new facilities, followed by those involving the expansion of existing manufacturing facilities (28%). Further, 50% of the expansion initiatives mentioned in the report, were in undertaken by stakeholder companies in Europe, followed North America (39%). Big pharma players have also been active in this upcoming field Around 60% of the initiatives undertaken by big pharma were reported in the period 2016-2020. Of these, 57% involved the establishment of strategic partnerships with other industry stakeholders. It is worth highlighting that, in terms of type of biologic, close to 49% of these initiatives were focused on recombinant proteins. North America and Europe are anticipated to capture over 80% share (in terms of service revenues) of the market, by 2030 At present, more than 60% of the total revenues are generated from commercialized microbial biologics, and this trend is unlikely to change significantly in short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for microbial biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (10.3%), followed by Asia Pacific (9%). To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market/request-sample.html Key Questions Answered § Who are the leading CMOs engaged in the production of microbial biologics? § What are the preferred microbial systems for the development and manufacturing of biologics? § Which are the key microbial fermentation technology platforms currently available in the market? § What kind of partnership models are commonly adopted by stakeholders in this industry? § What are the various initiatives undertaken by the big pharma players engaged in this domain? § What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to the production of microbial biologics? § What are the key trends within the microbial contract biomanufacturing market? § How is the current and future market opportunity likely to be distributed across key market segments? The USD 9.3 billion (by 2030) financial opportunity within the microbial contract biomanufacturing market has been analyzed across the following segments: § Type of Product § API § FDF § Type of Biologic § Proteins § Enzymes § Growth Hormones § Antibody based Drugs § Others (plasmid DNA, probiotics, microbiome-based biologics) § Type of Microbial Expression System § Bacteria § Yeast § Others (Algae and fungi) § Scale of Operation § Commercial § Preclinical / Clinical § Type of End User § Small Companies § Mid-sized Companies § Large / Very Large Companies § Key Geographical Regions § North America § Europe § Asia Pacific § Middle East and North Africa § Latin America The report features inputs from eminent industry stakeholders, according to whom, currently, over 50% operations related to both API and FDF manufacturing of microbial biologics are outsourced to third party service providers. The report includes detailed transcripts of discussions held with the following experts: § Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals) § Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories) § Andrea Conforto (Sales and Marketing, Bioservices Director, Olon) § Max Rossetto (General Manager, Business Development, Luina Bio) § Rob van Dijk (Business Development Manager, WACKER Biotech) The research covers profiles of key players (listed below); each profile features an overview of the company, information related to its microbial manufacturing focused service portfolio, production facilities and capabilities, and an informed future outlook. § AGC Biologics § Aldevron § BioVectra § EirGenix § Etinpro § Eurogentec § Northway Biotechpharma § Ology Bioservices § Porton Biopharma § Stelis Biopharma For additional details, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Drug Repurposing Service Providers Market, 2020 – 2030 2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030 3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
  20. Technical advances, especially in the field of biotechnology, have led to the development of several next generation preventive vaccines, including recombinant vaccines, viral vector based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunological memory. To order this 250+ page report, which features 85+ figures and 125+ tables, please visit this link The USD 94 billion (by 2030) financial opportunity within the global preventive vaccine market has been analyzed across the following segments: § Route of Administration § Intramuscular § Subcutaneous § Oral § Intravenous § Others § Type of Vaccine § Pneumococcal Conjugate Vaccine § Human Papilloma Virus Vaccine § Rotavirus Vaccine § Influenza Vaccine § MMR Vaccine § Tetanus and Diphtheria Booster Vaccine § Varicella Vaccine § DTaP-Hib-IPV Vaccine § DTaP-HepB-Hib-IPV Vaccine § Others § Type of Vaccine API § Live, Attenuated Vaccine § Inactivated Vaccine § Conjugate Vaccine § Subunit Vaccine § Toxoid Vaccine § Others § Target Patient Population § Pediatric Patients § Adults § Key Players § GlaxoSmithKline § Merck § Sanofi Pasteur § Pfizer § Emergent BioSolutions § CSL § Others § Key Geographical Regions § North America § Europe § Asia Pacific § Rest of the World The Global Preventive Vaccines Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: § Bio Farma § Emergent BioSolutions § GC Pharma § GlaxoSmithKline § Janssen § Merck § Novavax § Pfizer § Sanofi Pasteur § Valneva Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Company Competitiveness Analysis 6. Company Profiles 7. Clinical Trial Analysis 8. Ongoing Vaccine Development Initiatives for Complex Conditions 9. Funding and Investment Analysis 10. Market Sizing and Opportunity Analysis 11. Case-in-Point: Contract Manufacturing of Vaccines 12. Concluding Remarks 13. Executive Insights 14. Appendix 1: Tabulated Data 15. Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html Contact Details Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  21. Roots Analysis has done a detailed report on Global Preventive Vaccines Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities. To order this 250+ page report, which features 85+ figures and 125+ tables, please visit this link Key Market Insights § More than 200 preventive vaccines, developed by both industry and non-industry players, are being evaluated in clinical stages of development § A variety of vaccine APIs, designed for administration via multiple routes of delivery, are presently being investigated; most such candidates are in the early stages of development § In order to achieve a competitive edge, vaccine developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent § Foreseeing a lucrative future in this domain, several private and public investors have invested close to USD 10 billion in vaccine development initiatives, across 170 instances, in the time period between 2015 and 2020 § Over the last few years, 1,400+ clinical trials evaluating various types of preventive vaccines have been registered, indicating the rapid pace of development in this field § Case-in-Point: Around 70 companies, situated in different regions across the globe, claim to provide contract development, fill / finish and regulatory support, in addition to manufacturing services § The market is anticipated to grow at a CAGR of 10.7%, till 2030, and the projected opportunity is likely to be distributed across various routes of administration, vaccine types and key geographical regions For more information, please visit https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Preventive Vaccines 3.2.1. Classification of Vaccines 3.2.1.1. Live, Attenuated Vaccines 3.2.1.2. Inactivated Vaccines 3.2.1.3. Subunit Vaccines 3.2.1.4. Toxoid Vaccines 3.2.1.5. DNA Vaccines 3.2.2. Key Components of a Vaccine Formulation 3.2.3. Production of Vaccines using Different Expression Systems 3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs) 3.2.3.2. Mammalian Expression Systems 3.2.3.3. Avian Expression Systems 3.2.3.4. Plant Expression Systems 3.2.3.5. Bacterial Expression Systems 3.2.3.6. Yeast Expression Systems 3.2.3.7. Insect Expression System 3.2.4. Routes of Vaccine Administration 3.2.4.1. Intramuscular Route 3.2.4.2. Subcutaneous Route 3.2.4.3. Oral Route 3.2.4.4. Intranasal Route 3.2.4.5. Intradermal Route 3.2.4.6. Inhalation 3.2.5. Clinical Development and Approval of Vaccines 3.2.6. Future Perspectives 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Preventive Vaccines: Overall Market Landscape 4.2.1. Marketed Vaccines Landscape 4.2.2. Clinical-Stage Vaccines Landscape 4.2.2.1. Analysis by Type of Developer 4.2.2.2. Analysis by Phase of Development 4.2.2.3. Analysis by Route of Administration 4.2.2.4. Analysis by Type of Vaccine API 4.2.2.5. Analysis by Dosage Form 4.2.2.6. Analysis by Dosage 4.2.2.7. Analysis by Target Disease Indication 4.2.2.8. Analysis by Target Patient Population 4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development 4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Methodology 5.3. Assumptions and Key Parameters 5.4. Competitiveness Analysis: Preventive Vaccine Developers 5.4.1. Preventive Vaccine Developers based in North America 5.4.2. Preventive Vaccine Developers based in Europe 5.4.3. Preventive Vaccine Developers based in Asia Pacific 6. COMPANY PROFILES 6.1. Chapter Overview 6.2. Bio Farma 6.2.1. Company Overview 6.2.2. Preventive Vaccines Portfolio 6.2.3. Recent Developments and Future Outlook 6.3. Emergent BioSolutions 6.3.1. Company Overview 6.3.2. Preventive Vaccines Portfolio 6.3.3. Recent Developments and Future Outlook 6.4. GC Pharma 6.4.1. Company Overview 6.4.2. Preventive Vaccines Portfolio 6.4.3. Recent Developments and Future Outlook 6.5. GlaxoSmithKline 6.5.1. Company Overview 6.5.2. Preventive Vaccines Portfolio 6.5.3. Recent Developments and Future Outlook 6.6. Janssen 6.6.1. Company Overview 6.6.2. Preventive Vaccines Portfolio 6.6.3. Recent Developments and Future Outlook 6.7. Merck 6.7.1. Company Overview 6.7.2. Preventive Vaccines Portfolio 6.7.3. Recent Developments and Future Outlook 6.8. Novavax 6.8.1. Company Overview 6.8.2. Preventive Vaccines Portfolio 6.8.3. Recent Developments and Future Outlook 6.9. Pfizer 6.9.1. Company Overview 6.9.2. Preventive Vaccines Portfolio 6.9.3. Recent Developments and Future Outlook 6.10. Sanofi Pasteur 6.10.1. Company Overview 6.10.2. Preventive Vaccines Portfolio 6.10.3. Recent Developments and Future Outlook 6.11. Valneva 6.11.1. Company Overview 6.11.2. Preventive Vaccines Portfolio 6.11.3. Recent Developments and Future Outlook 7. CLINICAL TRIAL ANALYSIS 7.1. Chapter Overview 7.2. Scope and Methodology 7.3. Preventive Vaccines: Clinical Trial Analysis 7.3.1. Analysis by Trial Registration Year 7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year 7.3.3. Analysis by Trial Phase 7.3.4. Analysis by Trial Recruitment Status 7.3.5. Analysis by Study Design 7.3.6. Analysis by Trial Focus Area 7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen) 7.3.8. Analysis by Target Disease Indication 7.3.9. Analysis by Type of Sponsor / Collaborator 7.3.10. Leading Industry Players: Analysis by Number of Registered Trials 7.3.11. Geographical Analysis by Number of Registered Trials 7.3.12. Geographical Analysis by Enrolled Patient Population 7.3.13. Geographical Analysis by Trial Recruitment Status 8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS 8.1. Chapter Overview 8.2. Coronavirus Disease (COVID-19) 8.2.1. Disease Overview 8.2.2. Global Burden of COVID-19 8.2.3. Current Treatment Landscape 8.2.4. Preventive Vaccines for COVID-19 8.2.4.1. Historical Background of COVID-19 Vaccine Research 8.2.4.2. COVID-19 and Affiliated Research Landscape 8.2.5. Funding Instances 8.2.6. Recent Developments 8.3. Ebola Virus Disease (EVD) 8.3.1. Disease Overview 8.3.2. Global Burden of EVD 8.3.3. Current Treatment Landscape 8.3.4. Preventive Vaccines for EVD 8.3.4.1. Historical Background of Ebola Virus Vaccine Research 8.3.4.2. Anti-Ebola Virus Vaccines and Affiliated Research Landscape 8.3.5. Funding Instances 8.3.6. Recent Developments 8.4. HIV/AIDS 8.4.1. Disease Overview 8.4.2. Global Burden of HIV/AIDS 8.4.3. Current Treatment Landscape 8.4.4. Preventive Vaccines for HIV/AIDS 8.4.4.1. Historical Background of HIV/AIDS Vaccine Research 8.4.4.2. Anti-HIV Vaccines and Affiliated Research Landscape 8.4.5. Funding Instances 8.4.6. Recent Developments 8.5. Malaria 8.5.1. Disease Overview 8.5.2. Global Burden of Malaria 8.5.3. Current Treatment Landscape 8.5.4. Preventive Vaccines for Malaria 8.5.4.1. Historical Background of Malaria Vaccine Research 8.5.4.2. Anti-Malaria Vaccines and Affiliated Research Landscape 8.5.5. Funding Instances 8.5.6. Recent Developments 8.6. Zika Virus Infection 8.6.1. Disease Overview 8.6.2. Global Burden of Zika Virus Infection 8.6.3. Current Treatment Landscape 8.6.4. Preventive Vaccines for Zika Virus Infection 8.6.4.1. Historical Background of Zika Virus Vaccine Research 8.6.4.2. Anti-Zika Virus Vaccines and Affiliated Research Landscape 8.6.5. Funding Instances 8.6.6. Recent Developments 9. FUNDING AND INVESTMENT ANALYSIS 9.1. Chapter Overview 9.2. Types of Funding 9.3. Preventive Vaccines: Funding and Investment Analysis 9.3.1. Analysis by Number of Funding Instances 9.3.2. Analysis by Amount Invested 9.3.3. Analysis by Type of Funding 9.3.4. Analysis by Amount Invested across Different Types of Vaccine API 9.3.5. Analysis by Focus Area 9.3.6. Analysis by Amount Invested by Different Type of Investors 9.3.7. Most Active Players: Analysis by Number of Funding Instances 9.3.8. Most Active Investors: Analysis by Number of Funding Instances 9.3.9. Analysis by Geography 9.3.9.1. Continent-wise Analysis 9.3.9.2. Country-wise Analysis 10. MARKET SIZING AND OPPORTUNITY ANALYSIS 10.1. Chapter Overview 10.2. Forecast Methodology and Key Assumptions 10.3. Overall Preventive Vaccines Market, 2020-2030 10.3.1. Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration 10.3.2. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine 10.3.3. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API 10.3.4. Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population 10.3.5. Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions 10.3.5.1. Preventive Vaccines Market in North America, 2020-2030 10.3.5.1.1. Preventive Vaccines Market in the US, 2020-2030 10.3.5.1.2. Preventive Vaccines Market in Mexico, 2020-2030 10.3.5.1.2. Preventive Vaccines Market in Canada, 2020-2030 10.3.5.2. Preventive Vaccines Market in Europe, 2020-2030 10.3.5.2.1. Preventive Vaccines Market in Spain, 2020-2030 10.3.5.2.2. Preventive Vaccines Market in the UK, 2020-2030 10.3.5.2.3. Preventive Vaccines Market in Italy, 2020-2030 10.3.5.2.4. Preventive Vaccines Market in France, 2020-2030 10.3.5.2.5. Preventive Vaccines Market in Germany, 2020-2030 10.3.5.2.6. Preventive Vaccines Market in Rest of Europe, 2020-2030 10.3.5.3. Preventive Vaccines Market in Asia Pacific, 2020-2030 10.3.5.3.1. Preventive Vaccines Market in India, 2020-2030 10.3.5.3.2. Preventive Vaccines Market in China, 2020-2030 10.3.5.3.3. Preventive Vaccines Market in Australia, 2020-2030 10.3.5.3.4. Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030 10.3.5.4. Preventive Vaccines Market in Rest of the World, 2020-2030 11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES 11.1. Chapter Overview 11.2. Vaccine Contract Manufacturing 11.2.1. Addressing an Unmet Need 11.2.2. Commonly Outsourced Operations 11.2.3. Selecting a CMO Partner 11.2.4. Advantages of Outsourcing Manufacturing Services 11.2.5. Associated Risks and Challenges 11.3. Vaccine Contract Manufacturing: Overall Market Landscape 11.3.1. Analysis by Year of Establishment 11.3.2. Analysis by Company Size 11.3.3. Analysis by Scale of Operation 11.3.4. Analysis by Location of Headquarters 11.3.5. Analysis by Location of Manufacturing Facilities 11.3.6. Analysis by Type of Service(s) Offered 11.3.7. Analysis by Expression System Used 11.3.8. Analysis by Type of Vaccine Manufactured 11.3.9. Analysis by Type of Vaccine Manufactured and Location of Headquarters 12. CONCLUDING REMARKS 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Alopexx 13.2.1. Company Snapshot 13.2.2. Interview Transcript: Daniel R. Vlock, Chief Executive Officer 14. APPENDIX 1: TABULATED DATA 15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Contact Details Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  22. Although vaccines were solely responsible for the global eradication of smallpox (1980) and polio (2015), several vaccine-preventable diseases, such as measles and mumps, are still a threat; COVID-19 has been recently added to the list Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Preventive Vaccines Market, 2020-2030”. The report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes: § A detailed assessment of the current market landscape, featuring clinical-stage preventive vaccines. § A competitiveness analysis of preventive vaccine developers, featuring insightful pictorial summaries and representations. § Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. § An in-depth analysis of the completed, ongoing and planned trials of various preventive vaccines. § An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, Ebola virus disease, HIV/AIDS, malaria and zika virus infection. § An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March). § A case study on contract manufacturing landscape for vaccines, featuring the CMOs engaged in this domain. § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) § Route of Administration § Intramuscular § Subcutaneous § Oral § Intravenous § Others § Type of Vaccine § Pneumococcal Conjugate Vaccine § Human Papilloma Virus Vaccine § Rotavirus Vaccine § Influenza Vaccine § MMR Vaccine § Tetanus and Diphtheria Booster Vaccine § Varicella Vaccine § DTaP-Hib-IPV Vaccine § DTaP-HepB-Hib-IPV Vaccine § Others § Type of Vaccine API § Live, Attenuated Vaccine § Inactivated Vaccine § Conjugate Vaccine § Subunit Vaccine § Toxoid Vaccine § Others § Target Patient Population § Pediatric Patients § Adults § Key Players § GlaxoSmithKline § Merck § Sanofi Pasteur § Pfizer § Emergent BioSolutions § CSL § Others § Key Geographical Regions § North America § Europe § Asia Pacific § Rest of the World Key companies covered in the report § Bio Farma § Emergent BioSolutions § GC Pharma § GlaxoSmithKline § Janssen § Merck § Novavax § Pfizer § Sanofi Pasteur § Valneva For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html Other Recent Offerings § Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development § Novel Vaccine Delivery Devices Market, 2019-2030 [COVID-19 SERIES] § Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030 [COVID-19 SERIES] About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  23. The production of radiopharmaceuticals as compared to traditional pharmaceuticals is a multifaceted procedure and requires specialized facilities, equipment and operational expertise. Further, owing to its inherent hazardous nature, radiopharmaceuticals have a complex regulatory market authorization process. Consequently, a number of innovator companies have demonstrated a preference for outsourcing radiopharmaceutical manufacturing to contract service providers. To order this 320+ page report, which features 45+ figures and 100+ tables, please visit this - https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html The USD 6+ billion (by 2030) financial opportunity associated with nuclear medicine and radiopharmaceuticals manufacturing, has been analyzed across the following segments: § Target Disease Indication Breast Cancer Chronic Lymphocytic Leukemia Colorectal Cancer Head and Neck Cancer Lung Cancer Lupus Nephritis Melanoma Multiple Myeloma Primary Sjögren's Syndrome Others § Target Immune Checkpoint B7-H3 CD38 CD40 CD47 Others § Mechanism of Action Inhibitory Stimulatory § Therapeutic Modality Monoclonal Antibody Small Molecule § Type of Therapy Monotherapy Combination Therapy § Route of Administration Intravenous Subcutaneous Others § Key Geographical Regions North America Europe Asia-Pacific and the Rest of the World The Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report features the following companies, which we identified to be key players in this domain: § Advanced Accelerator Applications § Belgian Nuclear Research Center (SCK•CEN) § Cardinal Health § China Isotope & Radiation Corporation § Curium Pharma § DuChemBio § Eckert & Ziegler § Eczacibasi-Monrol § GE Healthcare § Jubilant DraxImage § Lantheus Medical Imaging § Nihon Medi-Physics § Nordion § PETNET Solutions § SinoTau Pharmaceuticals § SOFIE Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Current Market Landscape 5. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Current Market Landscape 6. Nuclear Medicine and Radiopharmaceuticals Manufacturers in North America 7. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Europe 8. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Asia-Pacific And Rest of The World 9. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Company Competitiveness Analysis 10. Partnerships and Collaborations 11. Production and Supply Chain of Medical Isotope Molybdenum-99 (Technetium-99m) 12. Market Forecast and Opportunity Analysis 13. Concluding Remarks 14. Executive Insights 15. Appendix 1: Tabulated Data 16. Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html Contact Details Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  24. The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applications, coupled with the introduction of theranostics, has opened up opportunities for companies having capabilities to manufacture nuclear medicine and radiopharmaceuticals Roots Analysis is pleased to announce the publication of its recent study, titled, “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” The report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following: § A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. § An insightful four-dimensional comparison of the radiopharmaceutical manufacturers. § Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players). § An analysis of recent partnerships and collaborations inked in this domain since 2017. § A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m). § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) § Target Therapeutic Area § Cardiology § Neurology § Oncology § Thyroid § Others Application Area § Diagnostic § Therapeutic § Type of Diagnostic Radiopharmaceuticals § PET § SPECT § Type of Therapeutic Radiopharmaceuticals § Alpha Emitters § Beta Emitters § Others § Purpose of Production § In-House § Outsourcing Key Geographical Region § North America § Europe § Asia-Pacific and the Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies § J James Davis, Vice President Quality / R&D, Shertech Laboratories § Andreas Fotopoulos, Professor of Nuclear Medicine, University of Ioannina Medical School § Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen § Michael van Dam, Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology § Anonymous, ITM Isotopen Technologien München Key companies covered in the report § Advanced Accelerator Applications § Belgian Nuclear Research Center (SCK•CEN) § Cardinal Health § China Isotope & Radiation Corporation § Curium Pharma § DuChemBio § Eckert & Ziegler § Eczacibasi-Monrol § GE Healthcare § Jubilant DraxImage § Lantheus Medical Imaging § Nihon Medi-Physics § Nordion § PETNET Solutions § SinoTau Pharmaceuticals § SOFIE For more information please click on the following link: https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html Other Recent Offerings 1. High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030 2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030 3. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030 4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  25. Roots Analysis has done a detailed study on Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030., covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Key Market Insights § Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologies § Industry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domain § Majority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry players § Stakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industry § The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indications § Considering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savings § The market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Overview of Drug Development 3.3. Drug Discovery Process 3.3.1. Target Identification 3.3.2. Target Validation 3.3.3. Hit Generation 3.3.4. Hit-to-Lead 3.3.5. Lead Optimization 1.4. High-Throughput Screening (HTS) and its Limitations 3.5. Fragment-based Drug Discovery (FBDD) Press Release: Variation 2 (Format 3) 3.5.1. FBDD Strategies 3.5.2. Screening Techniques Used in FBDD 3.6. Challenges Related to FBDD 3.7. Future Perspectives 4. CURRENT MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Fragment-based Drug Discovery: List of Library and Service Providers 4.2.1. Analysis by Year of Establishment of Company 4.2.2. Analysis by Company Size and Geographical Location 4.2.3. Leading Library and Service Providers: Analysis by Number of Products 4.2.4. Analysis by Geography 4.2.5. Analysis by Type of Service Offered 4.2.6. Analysis by Type of Technique Used 4.2.7. Analysis by Other Services Offered 4.2.8. Analysis by End User 4.3. Fragment-based Drug Discovery: List of Libraries and Technologies 4.3.1. Analysis by Type of Product 5. COMPANY PROFILES: FRAGMENT-BASED DRUG DISCOVERY LIBRARY AND SERVICE PROVIDERS 5.1. Chapter Overview 5.2. 2bind 5.2.1. Recent Developments and Future Outlook 5.3. Charles River Laboratories 5.3.1. Recent Developments and Future Outlook 5.4. ChemAxon 5.4.1. Recent Developments and Future Outlook 5.5. ComInnex 5.5.1. Recent Developments and Future Outlook 5.6. Creative Biolabs 5.6.1. Recent Developments and Future Outlook 5.7. Creative Biostructure 5.8. CRELUX 5.8.1. Recent Developments and Future Outlook 5.9. Domainex 5.9.1. Recent Developments and Future Outlook 5.10. Evotec 5.10.1. Recent Developments and Future Outlook 5.11. Red Glead Discovery 5.12. SARomics Biostructures 5.13. Shanghai ChemPartner 5.13.1. Recent Developments and Future Outlook Press Release: Variation 2 (Format 3) 5.14. Sygnature Discovery 5.14.1. Recent Developments and Future Outlook 5.15. Vernalis Research 5.15.1. Recent Developments and Future Outlook 6. PARTNERSHIPS AND COLLABORATIONS 6.1. Chapter Overview 6.2. Partnership Models 6.3. Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations 6.3.1. Analysis by Year of Partnership 6.3.2. Analysis by Type of Partnership 6.3.3. Analysis by Year of Partnership and Type of Partner 6.3.4. Most Active Players: Analysis by Number of Partnerships 6.3.5. Regional Analysis 6.3.6. Intercontinental and Intracontinental Agreements 7. KEY ACQUISITION TARGETS 7.1. Chapter Overview 7.2. Scope and Methodology 7.3. Scoring Criteria and Key Assumptions 7.4. Potential Strategic Acquisition Targets in North America 7.5. Potential Strategic Acquisition Targets in Europe 7.6. Potential Strategic Acquisition Targets in Asia-Pacific 7.7. Concluding Remarks 8. COMPANY COMPETITIVENESS ANALYSIS 8.1. Chapter Overview 8.2. Methodology 8.3. Key Parameters 8.4. Competitiveness Analysis: Fragment-based Drug Discovery Library and Service Providers 8.4.1. Fragment-based Drug Discovery Library and Service Providers based in North America 8.4.2. Fragment-based Drug Discovery Library and Service Providers based in Europe 8.4.3. Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific 9. COST SAVING ANALYSIS 9.1. Chapter Overview 9.2. Key Assumptions and Parameters 9.3. Methodology 9.4. Overall Cost Saving Potential Associated with FBDD, 2020-2030 9.5. Concluding Remarks 10. MARKET FORECAST AND OPPORTUNITY ANALYSIS 10.1. Chapter Overview 10.2. Key Assumptions and Forecast Methodology 10.3. Global Fragment-based Drug Discovery Market, 2020-2030 10.4. Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030 10.4.1. Fragment-based Drug Discovery Market for X-ray Crystallography, 2020-2030 10.4.2. Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030 10.4.3. Fragment-based Drug Discovery Market for Surface Plasmon Resonance, 2020-2030 10.4.4. Fragment-based Drug Discovery Market for Other Screening Techniques, 2020-2030 10.5. Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030 10.5.1. Fragment-based Drug Discovery Market for Library Screening, 2020-2030 Press Release: Variation 2 (Format 3) 10.5.2. Fragment-based Drug Discovery Market for Fragment Screening, 2020-2030 10.5.3. Fragment-based Drug Discovery Market for Fragment Optimization, 2020-2030 10.6. Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030 10.6.1. Fragment-based Drug Discovery Market for Industry Players, 2020-2030 10.6.2. Fragment-based Drug Discovery Market for Non-industry Players, 2020-2030 10.7. Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030 10.7.1. Fragment-based Drug Discovery Market in the US, 2020-2030 10.7.2. Fragment-based Drug Discovery Market in Canada, 2020-2030 10.7.3. Fragment-based Drug Discovery Market in the UK, 2020-2030 10.7.4. Fragment-based Drug Discovery Market in France, 2020-2030 10.7.5. Fragment-based Drug Discovery Market in Germany, 2020-2030 10.7.6. Fragment-based Drug Discovery Market in Spain, 2020-2030 10.7.7. Fragment-based Drug Discovery Market in Italy, 2020-2030 10.7.8. Fragment-based Drug Discovery Market in Rest of Europe, 2020-2030 10.7.9. Fragment-based Drug Discovery Market in China, 2020-2030 10.7.10. Fragment-based Drug Discovery Market in Japan, 2020-2030 10.7.11. Fragment-based Drug Discovery Market in India, 2020-2030 10.7.12. Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, 2020- 2030 11. EXECUTIVE INSIGHTS 11.1. Chapter Overview 11.2. Edelris 11.2.1. Company Snapshot 11.2.2. Interview Transcript: Jean-Yves Ortholand, Co-founder & Chief Executive Officer 11.3. SARomics Biostructures 11.3.1. Company Snapshot 11.3.2. Interview Transcript: Björn Walse, Chief Executive Officer 12. CONCLUDING REMARKS 13. APPENDIX 1: TABULATED DATA 14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Contact Details Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
×
  • Create New...